Analyst Geoff Meacham from Citi maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report) and keeping the price target at $52.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Geoff Meacham’s rating is based on several promising developments at Kymera Therapeutics. The company has recently provided a positive update on its pipeline and financial status, including the introduction of a new immunology asset, the IRF5 degrader. This new asset, KT-579, has shown potential in preclinical studies for treating conditions like Lupus and rheumatoid arthritis, which adds to the company’s growth prospects.
Additionally, Kymera has maintained its timelines for key data readouts, such as the KT-621 phase 1 healthy volunteer trial scheduled for June 2025, and the phase 1b trial for atopic dermatitis later in the year. The strategic decision to discontinue the TYK2 degrader development is seen as a prudent move to extend the company’s capital runway. These factors, combined with a healthy cash position expected to last into the first half of 2028, suggest a strong potential for value creation, supporting the Buy rating.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KYMR in relation to earlier this year.